13-Jan-2026 10:03 PM CST - Yahoo Finance Top Picks 2026- Pfizer Inc. PFE As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus,
13-Jan-2026 2:02 PM CST - Yahoo Finance JPM26: Pfizer's Metsera deal supercharges its obesity strategy Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual JP Morgan Healthcare conference on January 12,
13-Jan-2026 5:34 AM CST - Yahoo Finance Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
13-Jan-2026 4:11 AM CST - Seeking Alpha Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.
12-Jan-2026 4:26 PM CST - Yahoo Finance UBS Likes Pfizer's MTSR Obesity Deal but Stays Neutral on PFE Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer's revenue outlook,
9-Jan-2026 6:59 AM CST - Seeking Alpha Pfizer inks licensing deal with Madrigal for MASH candidate Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer's (PFE) experimental MASH therapy ervogastat. Read more here.
8-Jan-2026 6:55 PM CST - Yahoo Finance How Pfizer's AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer's historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs.
13-Jan-2026 10:03 PM CST - Yahoo Finance Top Picks 2026- Pfizer Inc. PFE As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus,
13-Jan-2026 2:02 PM CST - Yahoo Finance JPM26: Pfizer's Metsera deal supercharges its obesity strategy Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual JP Morgan Healthcare conference on January 12,
13-Jan-2026 5:34 AM CST - Yahoo Finance Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
13-Jan-2026 4:11 AM CST - Seeking Alpha Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.
12-Jan-2026 4:26 PM CST - Yahoo Finance UBS Likes Pfizer's MTSR Obesity Deal but Stays Neutral on PFE Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer's revenue outlook,
9-Jan-2026 6:59 AM CST - Seeking Alpha Pfizer inks licensing deal with Madrigal for MASH candidate Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer's (PFE) experimental MASH therapy ervogastat. Read more here.
8-Jan-2026 6:55 PM CST - Yahoo Finance How Pfizer's AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer's historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs.
